Who Buys Lisinopril from India — 450 Importers Behind a $60.4M Market

The importation of Lisinopril from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like MYLAN B.V. (Netherlands) and MYLAN IRELAND C/O ALLOGA RDC (Netherlands) function as intermediaries, procuring large volumes to supply regional markets. Their purchasing patterns are characterized by bulk orders and consistent procurement schedules to maintain steady supply chains.

• Pharmaceutical Companies: LUPIN PHARMACEUTICAL INC (United States) and GEDEON RICHTER PLC (Hungary) are manufacturers that import Lisinopril for formulation and distribution under their brand names. Their procurement is aligned with production cycles and market demand forecasts, often involving substantial quantities to ensure production continuity.

• Re-exporters: Entities such as APL SWIFT SERVICES (MALTA) LTD. (Malta) import Lisinopril with the intent to distribute it to other markets. Their purchasing behavior is influenced by global demand trends and regulatory considerations in target markets, leading to variable order sizes and frequencies.

• Contract Manufacturers: Companies like BROWN AND BURK UK LIMITED (United Kingdom) may import Lisinopril to manufacture finished pharmaceutical products for other brands or markets. Their procurement is typically project-based, with volumes and schedules dictated by contractual agreements.

Understanding these segments is crucial for tailoring supply strategies, as each has unique requirements and operational dynamics.

Import regulations for Lisinopril vary across the top importing countries:

• Netherlands:
• Regulatory Authority: Medicines Evaluation Board (MEB).
• Import Registration Process: Requires submission of a marketing authorization application, including quality, safety, and efficacy data.
• Estimated Timeline: Approximately 210 days, subject to completeness of the application.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049071 are typically exempt from import duties within the EU.

• United States:
• Regulatory Authority: Food and Drug Administration (FDA).
• Import Registration Process: Requires an approved Abbreviated New Drug Application (ANDA) for generic drugs, along with facility registration and compliance with Current Good Manufacturing Practices (CGMP).
• Estimated Timeline: ANDA approval can take 10 months or more, depending on the review process.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049071 are generally duty-free.

• Nigeria:
• Regulatory Authority: National Agency for Food and Drug Administration and Control (NAFDAC).
• Import Registration Process: Involves submission of a registration dossier, facility inspection, and product testing.
• Estimated Timeline: Approximately 6 to 12 months, depending on the complexity of the application.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049071 are subject to a 5% import duty.

• United Kingdom:
• Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
• Import Registration Process: Requires a marketing authorization, including submission of quality, safety, and efficacy data.
• Estimated Timeline: Approximately 210 days, subject to the application’s completeness.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049071 are typically exempt from import duties.

• Georgia:
• Regulatory Authority: State Regulation Agency for Medical Activities.
• Import Registration Process: Requires submission of a registration dossier, including product samples and manufacturing documentation.
• Estimated Timeline: Approximately 6 months, depending on the review process.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049071 are subject to a 0% import duty.

Compliance with these regulations is essential for market entry and sustained operations in these countries.

The demand for Lisinopril in importing countries is driven by several factors:

• Disease Prevalence: Hypertension and cardiovascular diseases are leading health concerns globally. The World Health Organization (WHO) reports that cardiovascular diseases account for approximately 31% of all global deaths as of 2023.

• Government Healthcare Programs: Many countries have implemented programs to manage non-communicable diseases. For instance, the United Kingdom's National Health Service (NHS) provides comprehensive coverage for hypertension management, increasing the demand for antihypertensive medications like Lisinopril.

• Universal Health Coverage Expansion: Countries expanding health coverage, such as Nigeria's National Health Insurance Scheme (NHIS), are increasing access to essential medicines, thereby boosting demand.

• WHO Essential Medicines List Procurement: Lisinopril's inclusion in the WHO Essential Medicines List encourages its procurement by international health organizations and governments, ensuring its availability in public health systems.

• Tender-Based Purchasing: Many governments and large healthcare providers procure medicines through competitive tendering processes, which can lead to substantial orders for Lisinopril.

With 450 buyers across 94 countries, the market for Lisinopril presents significant opportunities for suppliers, especially in regions with rising cardiovascular disease prevalence and expanding healthcare access.

The importation of Lisinopril from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like MYLAN B.V. (Netherlands) and MYLAN IRELAND C/O ALLOGA RDC (Netherlands) function as intermediaries, procuring large volumes to supply regional markets. Their purchasing patterns are characterized by bulk orders and consistent procurement schedules to maintain steady supply chains.

• Pharmaceutical Companies: LUPIN PHARMACEUTICAL INC (United States) and GEDEON RICHTER PLC (Hungary) are manufacturers that import Lisinopril for formulation and distribution under their brand names. Their procurement is aligned with production cycles and market demand forecasts, often involving substantial quantities to ensure production continuity.

• Re-exporters: Entities such as APL SWIFT SERVICES (MALTA) LTD. (Malta) import Lisinopril with the intent to distribute it to other markets. Their purchasing behavior is influenced by global demand trends and regulatory considerations in target markets, leading to variable order sizes and frequencies.

• Contract Manufacturers: Companies like BROWN AND BURK UK LIMITED (United Kingdom) may import Lisinopril to manufacture finished pharmaceutical products for other brands or markets. Their procurement is typically project-based, with volumes and schedules dictated by contractual agreements.

Understanding these segments is crucial for tailoring supply strategies, as each has unique requirements and operational dynamics.

Import regulations for Lisinopril vary across the top importing countries:

• Netherlands:
• Regulatory Authority: Medicines Evaluation Board (MEB).
• Import Registration Process: Requires submission of a marketing authorization application, including quality, safety, and efficacy data.
• Estimated Timeline: Approximately 210 days, subject to completeness of the application.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049071 are typically exempt from import duties within the EU.

• United States:
• Regulatory Authority: Food and Drug Administration (FDA).
• Import Registration Process: Requires an approved Abbreviated New Drug Application (ANDA) for generic drugs, along with facility registration and compliance with Current Good Manufacturing Practices (CGMP).
• Estimated Timeline: ANDA approval can take 10 months or more, depending on the review process.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049071 are generally duty-free.

• Nigeria:
• Regulatory Authority: National Agency for Food and Drug Administration and Control (NAFDAC).
• Import Registration Process: Involves submission of a registration dossier, facility inspection, and product testing.
• Estimated Timeline: Approximately 6 to 12 months, depending on the complexity of the application.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049071 are subject to a 5% import duty.

• United Kingdom:
• Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
• Import Registration Process: Requires a marketing authorization, including submission of quality, safety, and efficacy data.
• Estimated Timeline: Approximately 210 days, subject to the application’s completeness.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30049071 are typically exempt from import duties.

• Georgia:
• Regulatory Authority: State Regulation Agency for Medical Activities.
• Import Registration Process: Requires submission of a registration dossier, including product samples and manufacturing documentation.
• Estimated Timeline: Approximately 6 months, depending on the review process.
• Import Tariff/Duty: Pharmaceuticals under HS Code 30049071 are subject to a 0% import duty.

Compliance with these regulations is essential for market entry and sustained operations in these countries.

The demand for Lisinopril in importing countries is driven by several factors:

• Disease Prevalence: Hypertension and cardiovascular diseases are leading health concerns globally. The World Health Organization (WHO) reports that cardiovascular diseases account for approximately 31% of all global deaths as of 2023.

• Government Healthcare Programs: Many countries have implemented programs to manage non-communicable diseases. For instance, the United Kingdom's National Health Service (NHS) provides comprehensive coverage for hypertension management, increasing the demand for antihypertensive medications like Lisinopril.

• Universal Health Coverage Expansion: Countries expanding health coverage, such as Nigeria's National Health Insurance Scheme (NHIS), are increasing access to essential medicines, thereby boosting demand.

• WHO Essential Medicines List Procurement: Lisinopril's inclusion in the WHO Essential Medicines List encourages its procurement by international health organizations and governments, ensuring its availability in public health systems.

• Tender-Based Purchasing: Many governments and large healthcare providers procure medicines through competitive tendering processes, which can lead to substantial orders for Lisinopril.

With 450 buyers across 94 countries, the market for Lisinopril presents significant opportunities for suppliers, especially in regions with rising cardiovascular disease prevalence and expanding healthcare access.